文献速递生殖医学

辅助生殖技术中补充重组黄体生成素:系统综述

Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review.
PubMed 文献 · Fertil Steril · 2018-01-01

该系统综述评估重组人黄体生成素(r-hLH)补充在辅助生殖技术卵巢刺激中特定亚组患者的作用。结果显示r-hLH补充可能对卵巢储备参数正常但对r-hFSH单药治疗低反应者及36-39岁女性有益,对GnRH拮抗剂联合治疗的年轻正常反应者无获益证据,对GnRH类似物抑制内源性LH者及低反应者仍存争议,预防卵巢过度刺激综合征需进一步研究。

要点

  • r-hLH补充可能对卵巢储备正常但意外低反应者及36-39岁女性有益。
  • 年轻(<35岁)正常反应者联合GnRH拮抗剂时无r-hLH获益证据。
  • GnRH类似物抑制内源性LH者及低反应者使用r-hLH仍存争议。

核心结论

  • 重组人LH可考虑用于低反应者和36-39岁女性。

研究设计与样本

  • 系统综述,研究人群为接受辅助生殖技术卵巢刺激的六类特定亚组患者。

主要发现

  • r-hLH补充似乎对卵巢刺激前卵巢储备参数正常且对r-hFSH单药治疗意外低反应的女性和36-39岁女性两个亚组有益。
  • 无证据表明r-hLH对联合GnRH拮抗剂治疗的年轻(<35岁)正常反应者有益。
  • 因GnRH类似物导致内源性LH水平抑制的女性和低反应者中使用r-hLH补充仍存争议。
  • 使用r-hLH补充预防卵巢过度刺激综合征的发生需进一步研究。

临床怎么用

  • 作者认为r-hLH可考虑用于低反应者和36-39岁女性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the role of recombinant human LH (r-hLH) supplementation in ovarian stimulation for ART in specific subgroups of patients. DESIGN: Systematic review. SETTING: Centers for reproductive care. PATIENT(S): Six populations were investigated: 1) women with a hyporesponse to recombinant human FSH (r-hFSH) monotherapy; 2) women at an advanced reproductive age; 3) women cotreated with the use of a GnRH antagonist; 4) women with profoundly suppressed LH levels after the administration of GnRH agonists; 5) normoresponder women to prevent ovarian hyperstimulation syndrome; and 6) women with a "poor response" to ovarian stimulation, including those who met the European Society for Human Reproduction and Embryology Bologna criteria. INTERVENTION(S): Systematic review. MAIN OUTCOME MEASURE(S): Implantation rate, number of oocytes retrieved, live birth rate, ongoing pregnancy rate, fertilization rate, and number of metaphase II oocytes. RESULT(S): Recombinant hLH supplementation appears to be beneficial in two subgroups of patients: 1) women with adequate prestimulation ovarian reserve parameters and an unexpected hyporesponse to r-hFSH monotherapy; and 2) women 36-39 years of age. Indeed, there is no evidence that r-hLH is beneficial in young (<35 y) normoresponders cotreated with the use of a GnRH antagonist. The use of r-hLH supplementation in women with suppressed endogenous LH levels caused by GnRH analogues and in poor responders remains controversial, whereas the use of r-hLH supplementation to prevent the development of ovarian hyperstimulation syndrome warrants further investigation. CONCLUSION(S): Recombinant hLH can be proposed for hyporesponders and women 36-39 years of age.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Alviggi C, Conforti A, Esteves SC, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018. PMID: 29653717. doi:10.1016/j.fertnstert.2018.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。